NCT05233618View on ClinicalTrials.gov

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

October 1, 2026

Conditions
MyelofibrosisChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Interventions
DRUG

Tagraxofusp

inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles

Trial Locations (2)

19107

RECRUITING

Thomas Jefferson University, Philadelphia

22901

RECRUITING

University of Virginia, Charlottesville

All Listed Sponsors
lead

Karen Ballen, MD

OTHER